Document Detail


The PARACHUTE IV trial design and rationale: Percutaneous ventricular restoration using the parachute device in patients with ischemic heart failure and dilated left ventricles.
MedLine Citation:
PMID:  23537969     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
BACKGROUND: Left ventricle (LV) remodeling after anterior wall myocardial infarction leads to increased LV volumes, myocardial stress, and, ultimately, heart failure (HF). Patients have high morbidity and mortality risk, and treatment remains limited. Percutaneous ventricular restoration (PVR) therapy using the Parachute device, a fluoropolymer membrane stretched over a nitinol conical frame, is a novel approach to partition off the damaged myocardium. In the European and United States PARACHUTE feasibility trials, the observed rates of death or rehospitalization for HF were <17% at 12 months. These data compare favorably with historical data and support the need of a randomized trial to determine the clinical efficacy of PVR on outcomes for patients with ischemic HF.
OBJECTIVE: To determine the safety and efficacy of PVR utilizing a LV partitioning device, Parachute, in a randomized clinical trial compared with optimal medical therapy.
METHODS: This US pivotal trial is approved by the Food and Drug Administration (ClinicalTrials.gov Identifier: NCT01286116) and will randomly assign (1:1) 478 patients with New York Heart Association class III-IV ischemic HF, akinetic or dyskinetic LV wall abnormality, and ejection fraction between 15% and 35% to optimal medical therapy (control) versus Parachute device implantation in approximately 65 hospitals. The primary endpoint is death or rehospitalization for worsening HF. Sample size calculation assumes constant hazards and follow-up ≥12 months using an event-driven trial design.
CONCLUSIONS: We reported the rational and design of the first multicenter randomized trial to test the efficacy of PVR using the Parachute device to treat patients with ischemic HF and dilated LV.
Authors:
Marco A Costa; Michael Pencina; Serjan Nikolic; Thomas Engels; Barry Templin; William T Abraham
Related Documents :
2146489 - Collagen and the myocardium: fibrillar structure, biosynthesis and degradation in relat...
7759729 - Effect of captopril and enalapril on left ventricular geometry, function and collagen d...
15117889 - In vivo transfer of soluble tnf-alpha receptor 1 gene improves cardiac function and red...
11984749 - The renin-angiotensin system does not contribute to the endothelial dysfunction and inc...
8456979 - Ang ii receptors, c-myc, and c-jun in myocytes after myocardial infarction and ventricu...
19767889 - Myocardial remodelling induced by repeated low doses of isoproterenol.
23720419 - Embryonic cardiac chamber maturation: trabeculation, conduction, and cardiomyocyte prol...
21501389 - Echocardiographic assessment of atrial properties in single ventricles vs. normal contr...
20350309 - Cardiovascular magnetic resonance of the myocardium at risk in acute reperfused myocard...
Publication Detail:
Type:  Journal Article     Date:  2013-02-19
Journal Detail:
Title:  American heart journal     Volume:  165     ISSN:  1097-6744     ISO Abbreviation:  Am. Heart J.     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-03-29     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0370465     Medline TA:  Am Heart J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  531-6     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2013 Mosby, Inc. All rights reserved.
Affiliation:
University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Rationale and design of the ATTRACT Study: a multicenter randomized trial to evaluate pharmacomechan...
Next Document:  Sex-related effectiveness of bivalirudin versus abciximab and heparin in non-ST-segment elevation my...